Europe Biosimilar Insulin Glargine and Lispro Market to Cross $ 1.9 Billion by 2024
Ageing population and growing healthcare challenges
associated with diabetes to propel Europe biosimilar insulin glargine and
lispro market through 2024
According to
Tech Sci Research report, “Europe
Biosimilar Insulin Glargine & Lispro Market By End User, By Country,
Competition, Forecast & Opportunities, 2024”, Europe biosimilar insulin glargine and lispro market is anticipated
to surpass $ 1.9 billion by 2024 on account of growing expenditure on
healthcare and increasing prevalence of obesity and diabetes in the growing countries.
Cost-effectiveness and drug efficacy are the major factors for switching to
biosimilar insulin due to the high cost of insulin treatment. Thus, patient advocacy
groups, healthcare professionals, and policymakers, etc., are focusing on
manufacturing of biosimilar insulin which is expected to further drive Europe
biosimilar insulin glargine and lispro market during the forecast period. Germany is among the top ten countries with maximum
number of new cases of type 1 diabetes in children. However, owing to the high
competition among the major companies, the biosimilars will face competition
from new insulin products and can act as the major impediment to the growth of Europe
biosimilar insulin glargine and lispro market.
Browse XX market data Tables and XX Figures spread
through XXX Pages and an
in-depth TOC on " Europe Biosimilar Insulin Glargine and Lispro Market"
https://www.techsciresearch.com/report/europe-biosimilar-insulin-glargine-and-lispro-market/4278.html
Europe
biosimilar insulin glargine and lispro market can be segmented based on end
user, and country. On the basis of packaging, the market can be segmented into Vial,
Pen and Cartridge. Of all, Vial segment dominated Europe biosimilar insulin
glargine and lispro market until 2018 and is expected to maintain its dominance
over the forecast period as well on account of growing need for single dose
aseptic sterile packaging to prevent the use of preservatives coupled with its
increased use in liquid pharmaceutical applications which is boosting the demand for vials, especially in
applications like biosimilar insulin storage.
Sanofi,
Eli Lilly-Boehringer Ingelheim, Mylan-Biocon, Geropharm, Novo Nordisk,
Sandoz-Gan Lee, etc., are some of the leading players operating in Europe biosimilar
insulin glargine and lispro market. The companies operating in the market are
using strategies such as product launches, mergers and collaborations to boost
their share and expand their presence in the market.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4278
Customers can
also request for 10% free customization on this report.
“Europe biosimilar
insulin glargine and lispro market is anticipated to register a significant
growth during the next five years owing to the presence of the major players
such as Sanofi, Eli-Lilly, among others in the region. Moreover, growing
healthcare challenges associated with diabetes is further positively
influencing Europe biosimilar insulin glargine and lispro market.” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“Europe Biosimilar Insulin Glargine &
Lispro Market By End User, By Country, Competition, Forecast &
Opportunities, 2024” has evaluated
the future growth potential of Europe biosimilar insulin glargine and lispro market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in Europe biosimilar insulin glargine and lispro market.
About TechSci Research
TechSci
Research is a leading global market research firm publishing premium market
research reports. Serving 700 global clients with more than 600 premium market
research studies, TechSci Research is serving clients across 11 different
industrial verticals. TechSci Research specializes in research-based consulting
assignments in high growth and emerging markets, leading technologies and niche
applications. Our workforce of more than 100 fulltime Analysts and Consultants
employing innovative research solutions and tracking global and country
specific high growth markets helps TechSci clients to lead rather than follow
market trends.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]